2025年中国新上市抗实体瘤药物年度盘点:靶点、循证医学证据与发展趋势OA

This article reviews 33 novel anti-solid tumor drugs approved by the National Medical Products Administration(NMPA)in 2025,collecting detailed information and conducting comprehensive analysis.Statistical results show that nearly half of these new drugs target refractory molecular subtypes,including EGFR exon 20 insertion mutations,HER-2-activating mutations,KRAS G12C variations,and NTRK gene fusions,aligning with clinical needs where current treatment options are limited in later-line settings.By integrating public regulatory documents and phase Ⅲ clinical trial data,this study explores the mechanisms of action of these innovative drugs,summarizes existing evidence-based medical evidence,and analyzes their potential for clinical application.The applicable indications cover multiple cancer types,including lung cancer,breast cancer,digestive system tumors,urinary system tumors,and various rare solid tumors.These new drugs have achieved significant progress in efficacy,with objective response rates in later-line treatment for multiple cancers improving from less than 20%to over 40%.However,long-term safety data for some drugs still require observation in real-world settings.From a clinical perspective,they provide more feasible options for patients who previously had difficulty obtaining better treatments,but the core challenge lies in establishing precise correlations among molecular testing,evidence-based strength,and individual patient characteristics.The popularization of molecular testing,medical insurance coverage,and real-world observations will be key factors influencing the widespread clinical application of these drugs.